Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Core Insights - Aptevo Therapeutics reported that 89% of evaluable frontline AML patients achieved remission in combination therapy across two trials, with a notable 100% remission rate in Cohort 3 of the ongoing RAINIER trial [1][1][1] - The company introduced its first trispecific molecules, APVO451 and APVO452, aimed at overcoming immune suppression in certain solid tumors, utilizing a unique CRIS-7-derived CD3 binding domain [1][1][1] - Aptevo's CD3 T-cell engager portfolio has been expanded to five molecules, indicating growth in its therapeutic offerings [1][1][1] - The company raised $18.7 million in the third quarter and an additional $4.1 million since the quarter ended, extending its cash runway into the fourth quarter of 2026 [1][1][1] Financial Performance - The financial results for the quarter ended September 30, 2025, were reported alongside a business update, highlighting the company's ongoing development in immune-oncology therapeutics [1][1][1]